Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAVERSE: Ad26.Mos.HIV vs Ad26.Mos4.HIV in Healthy Adults
NCT02788045Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Ad26.Mos4.HIV in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With Solicited Local Adverse Events Post Vaccination at Day 344, Percentage of Participants With Solicited Systemic Adverse Events Post Vaccination at Day 344 and 3 more. Started Jul 2016; status: completed.
02
Drugs
Ad26.Mos4.HIV
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02788045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788045.